Island Pharmaceuticals

Pitt Street Research's Stuart Roberts highlighted Island Pharmaceuticals (ASX: ILA) on ausbiz, noting its promising work on drugs for diseases like dengue fever & Ebola. He sees 2025 as pivotal for life sciences data & key trial phases. Watch 👇 #ILA #antiviraltherapeutics #ASX #ASXnews https://lnkd.in/diiv7Yjy

Island Pharmaceuticals (ASX: ILA) is pleased to provide the Company's Half Year Report ended 31 December 2024: https://lnkd.in/gxrhMkPX #antiviraltherapeutics #ILA #ASX #ASXnews #ASXstocks

Most Investor Stream subscribers know Jason Carroll as the Chief Executive of Tryp Therapeutics (ASX:TYP), the clinical-stage biotech making key advancements in the field of precision psychedelics. Jason is also one of the largest shareholders in another ASX biotech, Island Pharmaceuticals, (ASX:ILA) which specialises in unique clinically-backed solutions for the treatment of Dengue fever. Turning from the C-suite to the buy-side, Jason delves into what attracted him to Island as an investment proposition, and using his unique vantage point into the global regulatory standards for international healthcare companies Jason delves into how Island is advancing its clinical trial program. WATCH 👇 ▶️ https://lnkd.in/gHJGZ8iP #ILA #biotech #dengue #denguefever #antiviraltherapeutics #health #ASX #ASXinterview Alex Paull David Foster

📺Via Investor Stream: Island Pharmaceuticals (ASX:ILA) CEO Dr David Foster joins Alex Paull of Investor Stream following the successful completion of subject dosing for the Phase 2b therapeutic (treatment) arm of the Company’s Phase 2a/b PROTECT clinical trial utilising ISLA-101 to combat dengue fever. David delves into ILA's strategy to achieve improved health outcomes in this field, why ILA's lead drug candidate could reshape how dengue is treated, and the latest on the clinical trial progress. Watch 👇 https://lnkd.in/gdarf8_x #dengue #denguefever #antiviraltherapeutics #ILA #ASX #ASXinterview

📺Via Investor Stream: Island Pharmaceuticals (ASX:ILA) CEO Dr David Foster joins Alex Paull of Investor Stream following the successful completion of subject dosing for the Phase 2b therapeutic (treatment) arm of the Company’s Phase 2a/b PROTECT clinical trial utilising ISLA-101 to combat dengue fever. David delves into ILA's strategy to achieve improved health outcomes in this field, why ILA's lead drug candidate could reshape how dengue is treated, and the latest on the clinical trial progress. Watch 👇 https://lnkd.in/gdarf8_x #dengue #denguefever #antiviraltherapeutics #ILA #ASX #ASXinterview

According to Peter Sanders from the ABC, the beginning of 2025 saw an alarming surge in mosquito-borne viruses across Queensland, Australia. With dengue cases more than tripling compared to previous years in the state, it is clear that dengue is spreading and growing in regions that have not historically been endemic – a highly concerning global trend of the past few years. The escalating situation in Queensland is a stark reminder of why proactive research and development of dengue therapeutics are critical. There is currently no treatment and limited viable vaccine options, leaving prevention and treatment of this disease an urgent unmet medical need.    Island Pharmaceuticals is currently running our Phase 2a/b clinical study exploring the potential use of our drug ISLA-101 as both a preventative and treatment for #dengue. We look forward to providing an update on the Phase 2b results in the coming months, as we continue to explore the possibility of finding a solution to this global health crisis.   https://lnkd.in/gfzXYfsS   #mosquitobornedisease #antiviraltherapeutics #ILA

Island Pharmaceuticals is pleased to release our December 2024 quarterly business activities update. It was a significant period for the company, highlighted by successful results from the Phase 2a prophylactic arm of our Phase 2a/b clinical trial in #dengue fever. Other key highlights included the appointment of Mr Phillip R Lynch as Executive Chairman, and a $3.5 million placement, ensuring we are well-funded to drive our clinical programs forward. CEO Dr David Foster said, “Q2 FY25 has been a pivotal quarter for Island Pharmaceuticals, marked by significant progress in our ISLA-101 Phase 2a/b PROTECT clinical trial in dengue fever. We're very pleased to have completed the dosing of subjects in the Phase 2a prophylactic arm and to have recorded positive safety and anti-dengue activity. These achievements demonstrate the potential of ISLA-101 to address the major unmet need for effective treatments against dengue fever." For further information, please refer to our announcement here: https://lnkd.in/dg2hQcvT

Island Pharmaceuticals is pleased to announce that all subjects have now been enrolled for the Phase 2b arm of the ISLA-101 Phase 2a/b clinical trial in dengue fever. Divided into two cohorts, the Phase 2a/b clinical trial aims to understand if ISLA-101 can be an effective prophylactic (preventative, Phase 2a) and/or therapeutic (treatment, Phase 2b) against a dengue infection. In the Phase 2b study, subjects were administered an attenuated strain of dengue virus first, before they are treated with ISLA-101 and then observed to see if the drug candidate can reduce virus level and symptoms. Island progressed to Phase 2b trial based on the recommendation of the Safety Review Committee, who determined that ISLA-101 was safe and exhibited antiviral activities upon reviewing the results of the Phase 2a study. All ten subjects for the Phase 2b clinical trial have now been enrolled, with initial results expected around April 2025. Full results from the unblinded data of both the Phase 2a and Phase 2b cohorts can be expected in Q4 FY2025. Island CEO and Managing Director Dr David Foster said: "We are pleased to have reached this important milestone in our PROTECT clinical trial. The enrolment of the final six subjects in the Phase 2b therapeutic arm is a significant advancement in our clinical trial, and towards better understanding the potential of ISLA-101 as a treatment for dengue fever." Read the full announcement via this link: https://lnkd.in/gawk6rji #mosquitobornedisease #antiviraltherapeutics #ILA

Island Pharmaceuticals is pleased to share a spotlight video by Stockhead, capturing the key milestones we have achieved in 2024 and what’s in store for 2025.    Watch the video via this link: https://lnkd.in/gYne5k7z   We look forward to keeping investors closely updated as we advance our clinical programs.   #infectiousdisease #antiviraltherapeutics #drugdevelopment #ILA

Island Pharmaceuticals' CEO David Foster sits down with Stockhead to discuss the company's latest progress, including the launch of a Phase 2b clinical trial for its lead drug ISLA-101.    With no specific treatment currently available, this trial brings hope to the millions affected by the debilitating disease of #denguefever.   Watch the video here to learn more about Island's innovative approach and the significance of this trial: https://lnkd.in/gHFk5Qtv   #antiviral #clinicaltrial #IslandPharmaceuticals